Results 61 to 70 of about 733 (138)
Background. Idecabtagene vicleucel (ide-cel, Abecma) is the first anti-BCMA CAR-T approved for refractory multiple myeloma (MM). Although pivotal trials have demonstrated its efficacy, real-world evidence is limited, especially in newly incorporated ...
L. Piquer Monsonis +12 more
doaj +1 more source
History of Hemotherapy at INCA
De forma cronológica, o artigo retrata a História da Hemoterapia no INCA.
Guadagnino, Maria da Conceição Muniz +2 more
openaire +1 more source
Platelet refractoriness caused by alloimmunization to anti-HLA antibodies remains present in daily hemotherapy: the frequent need for platelet transfusions may influence the long-term survival of treated patients. This study aimed to perform a systematic
Luana Joana Barreto Cabral +5 more
doaj +1 more source

